MedPath

Comorbidities in Type 2 Diabetes Mellitus

Not Applicable
Recruiting
Conditions
Type 2 Diabetes
Registration Number
NCT05874141
Lead Sponsor
New Valley University
Brief Summary

Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

Detailed Description

All-cause mortality rates have declined substantially in several high-income countries, including England.

A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.

Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.

Many studies have primarily focused on identifying multimorbidity patterns in the general population.

The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
288
Inclusion Criteria
  • Patients with type 2 diabetes.
Exclusion Criteria
  1. Patients with type 1 diabetes.
  2. Patients with secondary diabetes.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of participants with hypertensionAt time of inclusion in the study
Number of participants with thyroid disorderAt time of inclusion in the study
Number of participants with Liver diseaseAt time of inclusion in the study
Number of participants with Coronary heart diseaseAt time of inclusion in the study
Number of participants with InfectionsAt time of inclusion in the study
Number of participants with dyslipidemiaAt time of inclusion in the study
Number of participants with Diabetic kidney diseaseAt time of inclusion in the study
Number of participants with StrokeAt time of inclusion in the study
Number of participants with Peripheral arterial diseaseAt time of inclusion in the study
Number of participants with Diabetic eye diseaseAt time of inclusion in the study
Number of participants with Peripheral neuropathyAt time of inclusion in the study
Number of participants with CancerAt time of inclusion in the study
Secondary Outcome Measures
NameTimeMethod
Number of participants with controlled diabetes mellitus with correlation to the number of cormobidityAt time of inclusion in the study
Correlate the presence of each co-morbidity with the extent of diabetes controlAt time of inclusion in the study

Trial Locations

Locations (1)

New Valley University

🇪🇬

Kharga Oasis, Egypt

New Valley University
🇪🇬Kharga Oasis, Egypt
Asmaa N Hussein, MD
Contact
01065161752
asmaanady_1010@med.nvu.edu.eg

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.